Recombinant IL-10 has, therefore, been targeted to treat inflammatory diseases such as psoriasis and inflammatory bowel diseases (IBD), however with very limited clinical progress [1,4,5]. This evidence concerns the gene IL10 and inflammatory bowel disease.